Theriva Biologics, Inc.: Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patient
Theriva Biologics (NYSE American: TOVX) said the first patient was dosed in its VIRAGE2 Phase 2a trial testing more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma with gemcitabine/nab-paclitaxel. Enrollment is expected to finish in H2 2026, with initial data in Q3 2027.
How this was made
The 30-second read
Why it matters
The new information is the activation of VIRAGE2 with a defined dosing schedule and endpoints (safety/tolerability and viral genome levels), plus a stated timeline for initial data. This can shift expectations for trial execution and future Phase 3 design, but it does not change efficacy evidence yet.
Market read
A trial activation milestone for TOVX’s lead asset, with endpoints and timing that can influence biotech sentiment and positioning ahead of later pharmacodynamic and safety data.
What to watch
The trial is not powered for clinical efficacy endpoints; investors may overinterpret the prior VIRAGE Phase 2b survival signals versus what VIRAGE2 can actually demonstrate.
Background
VCN-01 (zabilugene almadenorepvec) is an oncolytic adenovirus intended to degrade tumor stroma and enhance immune and chemo activity. VIRAGE2 is designed to refine dosing frequency based on prior VIRAGE Phase 2b results and EMA/FDA feedback.
Ticker impact
Theriva Biologics (TOVX) reports first patient dosed in VIRAGE2 Phase 2a to test more frequent VCN-01 dosing in metastatic PDAC.
Likely modest positive bias near-term, with follow-through dependent on subsequent safety and pharmacodynamic readouts.
The article discloses a new, time-stamped event (first patient dosed) plus a timeline for initial data (Q3 2027), but it does not provide new efficacy results or regulatory outcomes.
Market effects
Adds incremental validation for oncolytic adenovirus strategies targeting tumor stroma in PDAC, potentially supportive for similar platform narratives.
Primarily US-listed biotech sentiment; trial site is in Spain but the issuer is US-listed.
EMA and FDA feedback are cited, reinforcing transatlantic regulatory engagement for this mechanism in PDAC.
Counterpoint
Because VIRAGE2 is a small, single-arm Phase 2a focused on tolerability and viral genome levels, the market may discount the milestone until pharmacodynamic endpoints are reported.
Key entities
- companyTheriva Biologics, Inc.
NYSE American-listed clinical-stage biotech developing VCN-01 for cancer, announcing first patient dosed in VIRAGE2.
- drug_candidateVCN-01 (zabilugene almadenorepvec)
Systemically administered oncolytic adenovirus; dosing frequency is being evaluated in VIRAGE2.
- clinical_trialVIRAGE2
Phase 2a, single-arm, open-label trial in metastatic PDAC testing more frequent repeated VCN-01 dosing with gemcitabine/nab-paclitaxel.
- regulatorEMA
Provided scientific advice cited as recognizing potential benefit from repeated VCN-01 dosing.
- regulatorFDA
Meeting feedback cited as recognizing potential benefit from repeated VCN-01 dosing.
